These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24518296)

  • 1. Discovery of simplified N²-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: efficient synthetic approaches, biological evaluations and molecular docking studies.
    Venkatesan G; Paira P; Cheong SL; Vamsikrishna K; Federico S; Klotz KN; Spalluto G; Pastorin G
    Bioorg Med Chem; 2014 Mar; 22(5):1751-65. PubMed ID: 24518296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists.
    Venkatesan G; Paira P; Cheong SL; Federico S; Klotz KN; Spalluto G; Pastorin G
    Eur J Med Chem; 2015 Mar; 92():784-98. PubMed ID: 25633494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives.
    Federico S; Redenti S; Sturlese M; Ciancetta A; Kachler S; Klotz KN; Cacciari B; Moro S; Spalluto G
    PLoS One; 2015; 10(12):e0143504. PubMed ID: 26625265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.
    Lenzi O; Colotta V; Catarzi D; Varano F; Squarcialupi L; Filacchioni G; Varani K; Vincenzi F; Borea PA; Dal Ben D; Lambertucci C; Cristalli G
    Bioorg Med Chem; 2011 Jun; 19(12):3757-68. PubMed ID: 21616671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies.
    Catarzi D; Colotta V; Varano F; Poli D; Squarcialupi L; Filacchioni G; Varani K; Vincenzi F; Borea PA; Dal Ben D; Lambertucci C; Cristalli G
    Bioorg Med Chem; 2013 Jan; 21(1):283-94. PubMed ID: 23171656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A
    Federico S; Margiotta E; Salmaso V; Pastorin G; Kachler S; Klotz KN; Moro S; Spalluto G
    Eur J Med Chem; 2018 Sep; 157():837-851. PubMed ID: 30144700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.
    Baraldi PG; Saponaro G; Aghazadeh Tabrizi M; Baraldi S; Romagnoli R; Moorman AR; Varani K; Borea PA; Preti D
    Bioorg Med Chem; 2012 Jan; 20(2):1046-59. PubMed ID: 22204739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
    Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
    J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,2,4-triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A₃ receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies.
    Catarzi D; Varano F; Poli D; Squarcialupi L; Betti M; Trincavelli L; Martini C; Dal Ben D; Thomas A; Volpini R; Colotta V
    Bioorg Med Chem; 2015 Jan; 23(1):9-21. PubMed ID: 25497490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonists.
    Federico S; Ciancetta A; Sabbadin D; Paoletta S; Pastorin G; Cacciari B; Klotz KN; Moro S; Spalluto G
    J Med Chem; 2012 Nov; 55(22):9654-68. PubMed ID: 23098605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.
    Baraldi PG; Cacciari B; Spalluto G; Pineda de las Infantas y Villatoro MJ; Zocchi C; Dionisotti S; Ongini E
    J Med Chem; 1996 Mar; 39(5):1164-71. PubMed ID: 8676354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists.
    Baraldi PG; Baraldi S; Saponaro G; Aghazadeh Tabrizi M; Romagnoli R; Ruggiero E; Vincenzi F; Borea PA; Varani K
    J Med Chem; 2015 Jul; 58(13):5355-60. PubMed ID: 26046697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the combination of optimal substitutions at the C²-, N⁵- and N⁸-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A₃ adenosine receptors?
    Cheong SL; Dolzhenko AV; Paoletta S; Lee EP; Kachler S; Federico S; Klotz KN; Dolzhenko AV; Spalluto G; Moro S; Pastorin G
    Bioorg Med Chem; 2011 Oct; 19(20):6120-34. PubMed ID: 21908194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
    Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
    J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists.
    Redenti S; Ciancetta A; Pastorin G; Cacciari B; Moro S; Spalluto G; Federico S
    Curr Top Med Chem; 2016; 16(28):3224-3257. PubMed ID: 27150365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen.
    Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Moro S; Klotz KN; Leung E; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2000 Dec; 43(25):4768-80. PubMed ID: 11123985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor.
    Preti D; Baraldi PG; Saponaro G; Romagnoli R; Aghazadeh Tabrizi M; Baraldi S; Cosconati S; Bruno A; Novellino E; Vincenzi F; Ravani A; Borea PA; Varani K
    J Med Chem; 2015 Apr; 58(7):3253-67. PubMed ID: 25780876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A₁ and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.
    Squarcialupi L; Colotta V; Catarzi D; Varano F; Betti M; Varani K; Vincenzi F; Borea PA; Porta N; Ciancetta A; Moro S
    Eur J Med Chem; 2014 Sep; 84():614-27. PubMed ID: 25063944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.
    Lenzi O; Colotta V; Catarzi D; Varano F; Poli D; Filacchioni G; Varani K; Vincenzi F; Borea PA; Paoletta S; Morizzo E; Moro S
    J Med Chem; 2009 Dec; 52(23):7640-52. PubMed ID: 19743865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.